China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

A stand-alone sequencing approach was accurate, cost effective and efficient for analyzing resistant pathogens and ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

Fintel reports that on February 10, 2025, Barclays downgraded their outlook for Illumina (NasdaqGS:ILMN) from Equal-Weight to ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Genomics is bringing in a new wave of money from an unlikely group of investors — health systems. More providers are ...